Biomaterial Database

Valbenazine in the treatment of tardive dyskinesia. 2019

Natalie Witek, and Cynthia Comella

Rush University Medical Center, Section of Movement Disorders, Rush Parkinson's Disease & Movement Disorders Program, 1725 W Harrison St., Suite 755, Chicago, IL 60612, USA.

Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 2017, valbenazine became the first US FDA-approved medication indicated for the treatment of TD. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. The FDA considered valbenazine a breakthrough therapy in 2014 given its underlying mechanism and its importance in addressing an unmet need, as there were no available FDA-approved medications indicated for TD. The advantages of valbenazine include once-daily dosing and a rapid onset of effect within 2 weeks of treatment initiation.

UI	MeSH Term	Description	Entries
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071057	Tardive Dyskinesia	Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE).	Tardive Dystonia,Dyskinesia, Tardive,Dyskinesias, Tardive,Dystonia, Tardive,Dystonias, Tardive,Tardive Dyskinesias,Tardive Dystonias
D013747	Tetrabenazine	A drug formerly used as an antipsychotic and treatment of various movement disorders. Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system.	Nitoman,Xenazine
D014633	Valine	A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.	L-Valine,L Valine
D050493	Vesicular Monoamine Transport Proteins	A family of vesicular amine transporter proteins that catalyze the transport and storage of CATECHOLAMINES and indolamines into SECRETORY VESICLES.	Monoamine Transporters, Vesicular,Vesicular Monoamine Transporter Proteins,Chromaffin Granule Amine Transporter,Monoamine Vesicular Transport Proteins,Monoamine Vesicular Transporter,VMAT-1 Vesicular Monoamine Transporter,VMAT2 Vesicular Monoamine Transporter,Vesicular Monoamine Transporter,Vesicular Monoamine Transporter 1,Vesicular Monoamine Transporter 2,Monoamine Transporter, Vesicular,VMAT 1 Vesicular Monoamine Transporter,Vesicular Monoamine Transporters,Vesicular Transporter, Monoamine
D018492	Dopamine Antagonists	Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.	Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine
D018759	Adrenergic Uptake Inhibitors	Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.	Adrenergic Reuptake Inhibitors,Inhibitors, Adrenergic Reuptake,Inhibitors, Adrenergic Uptake,Reuptake Inhibitors, Adrenergic,Uptake Inhibitors, Adrenergic